TY - JOUR

T1 - Anthropometrics and prognosis in diffuse large B-cell lymphoma

T2 - a multicentre study of 653 patients

AU - Bendtsen, Mette Dahl

AU - Munksgaard, Peter Svenssen

AU - Severinsen, Marianne Tang

AU - Bekric, Eric

AU - Brieghel, Christian

AU - Nielsen, Kristina Buchardi

AU - Brown, Peter de Nully

AU - Dybkær, Karen

AU - Johnsen, Hans Erik

AU - Bøgsted, Martin

AU - El-Galaly, Tarec Christoffer

PY - 2017

Y1 - 2017

N2 - Objective: The impact of body mass index (BMI) and body surface area (BSA) on survival in diffuse large B-cell lymphoma (DLBCL) is controversial. Recent studies show superior outcomes for overweight and obese patients. Patients and methods: A total of 653 R-CHOP(-like)-treated DLBCL patients were included in this retrospective cohort study. Patients, baseline clinicopathologic characteristics and treatment information were retrieved from the Danish Lymphoma Registry. Anthropometric measures were obtained from chemotherapy prescription charts. Results: Underweight (BMI <18.5 kg/m2) was associated with significantly worse progression-free survival (PFS) for male patients only in sex-stratified analyses (HR 3.92, 95% CI: 1.57–9.75, P = 0.003, for males; HR 1.65, 95% CI: 0.90–3.02, P = 0.107, for females). In multivariate analyses, underweight was associated with worse PFS for both sexes (HR 5.34, 95% CI: 2.07–13.79, P = 0.001, for males; HR 2.14, 95% CI: 1.12–4.08, P = 0.021, for females). Similar results were obtained in analyses of overall survival. In crude analyses, BSA <1.8 m2 was associated with worse PFS for men and women (HR 1.65, 95% CI: 1.03–2.65, P = 0.039, for men; HR 1.62, 95% CI: 1.03–2.56, P = 0.037, for women). In multivariate analyses, however, these associations diminished. Conclusions: Our study demonstrates that underweight DLBCL patients have worse outcomes following R-CHOP as compared to normal as well as overweight patients.

AB - Objective: The impact of body mass index (BMI) and body surface area (BSA) on survival in diffuse large B-cell lymphoma (DLBCL) is controversial. Recent studies show superior outcomes for overweight and obese patients. Patients and methods: A total of 653 R-CHOP(-like)-treated DLBCL patients were included in this retrospective cohort study. Patients, baseline clinicopathologic characteristics and treatment information were retrieved from the Danish Lymphoma Registry. Anthropometric measures were obtained from chemotherapy prescription charts. Results: Underweight (BMI <18.5 kg/m2) was associated with significantly worse progression-free survival (PFS) for male patients only in sex-stratified analyses (HR 3.92, 95% CI: 1.57–9.75, P = 0.003, for males; HR 1.65, 95% CI: 0.90–3.02, P = 0.107, for females). In multivariate analyses, underweight was associated with worse PFS for both sexes (HR 5.34, 95% CI: 2.07–13.79, P = 0.001, for males; HR 2.14, 95% CI: 1.12–4.08, P = 0.021, for females). Similar results were obtained in analyses of overall survival. In crude analyses, BSA <1.8 m2 was associated with worse PFS for men and women (HR 1.65, 95% CI: 1.03–2.65, P = 0.039, for men; HR 1.62, 95% CI: 1.03–2.56, P = 0.037, for women). In multivariate analyses, however, these associations diminished. Conclusions: Our study demonstrates that underweight DLBCL patients have worse outcomes following R-CHOP as compared to normal as well as overweight patients.

KW - body mass index

KW - body surface area

KW - diffuse large B-cell lymphoma

KW - prognosis

KW - survival

U2 - 10.1111/ejh.12835

DO - 10.1111/ejh.12835

M3 - Journal article

C2 - 27893172

AN - SCOPUS:85011416499

VL - 98

SP - 355

EP - 362

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 4

ER -